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Aim: The aim of this study was to compare the efficacies of goal-directed renal replacement therapy (GDRRT) and
daily hemofiltration (DHF) for treating acute kidney injury (AKI) patients after cardiac surgery.
Methods: In our retrospective study, we included 140 cardiac surgery AKI patients who were treated with renal
replacement therapy (RRT) from 2002 to 2010. Two patient groups, which comprised 70 patients who received DHF
from January 2002 to September 2008 and 70 patients treated with GDRRT from October 2009 to September 2010
were pair-wise compared regarding clinical outcomes, as well as the incidence of adverse events.
Results: In-hospital and 30-day mortality rates were 45.7% and 41.4% in the GDRRT and 48.6% and 54.3% in the
DHF group, respectively, but without statistically significant differences. GDRRT patients needed statistically
significantly shorter hospital and intensive care unit (ICU) stays, less frequent RRT, and shorter RRT sessions, whereas,
of 11 analyzed renal outcome parameters, 6 values, including percentage of complete renal recovery and time for
complete renal recovery, were significantly superior in the GDRRT group at the time of discharge. There was no
significant difference in the incidence of adverse events within the initial 72 treatment hours between the 2 groups.
Hospitalization expenses were less in GDRRT group than in DHF group.
Conclusion: The GDRRT approach is superior to DHF for improving renal outcome, as well as reducing the time
and cost of RRT therapy, for cardiac surgery AKI patients.
Keywords: Cardiac surgery, Acute kidney injury, Goal-directed renal replacement therapy, Daily hemofiltrationBackground
Cardiac surgery is a major cause of AKI in critically ill pa-
tients [1,2], and mortality among cardiopulmonary bypass
patients who need RRT after cardiac surgery is reported to
be 60-70% [3]. Although RRT is important in saving critic-
ally injured AKI patients, there is no consensus regarding
the optimal dose or form. There is insufficient evidence to
show that continuous renal replacement therapy (CRRT)
is better than intermittent renal replacement therapy
(IRRT) [4,5], and the efficacy of hybrid patterns, such as
sustained low-efficiency dialysis (SLED), has not yet been* Correspondence: tengmuyao@gmail.com
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unless otherwise stated.evaluated [6]. It is also unclear what the optimal dose is,
although it is argued that, for critically injured AKI pa-
tients, the dose should be at least 35 ml/kg/h of hemofil-
tration (HF) and an spKt/V value of 1.4 for hemodialysis
(HD) [7]. However, recent results from the Acute Renal
Failure Trial Network (ATN) study and the RENAL or
IVOIRE trials did not suggest the superiority of high-dose
intensive RRT [8,9]. Another issue is the optimal interven-
tion time, and most clinicians believe that early RRT can
improve outcomes, but there is no uniform standard as to
when RRT should be initiated [10-12]. The idea of a goal-
directed therapy (GDT) for critically ill patients was first
raised in 1973 by Shoemaker [13], and hemodynamic
GDT after surgery has been acknowledged as an effective
measure against postoperative hospital-acquired infections
[14]. In addition, various GDTs have been developed toThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[15,16] and non-cardiac surgery [17], and Goldstein et al.
have proposed an early goal-directed fluid therapy (EGDT)
for fluid management of critically ill AKI patients [18].
The concept of a GDRRT was first proposed by Mehta
et al. [19], but up to now, no detailed studies have been
published about GDRRT. We have been using GDRRT
since 2008, in which RRT goals were set up first, followed
by determinations of ultrafiltration rates, dialysate compo-
sitions, and goal-directed anticoagulant therapies. GDRRT
is supposed to be beneficial not only by providing extra
treatments when they are specifically indicated, but also
by allowing the earlier and guided use of fluids and pre-
venting the delivery of unnecessary treatments or fluid
removal when specific objectives have already been
achieved. In this retrospective analysis, we compared the
treatment outcomes of GDRRT and DHF in patients with
AKI after cardiac surgery.Methods
Patients
This retrospective, observational study was performed in a
cohort of 140 adult patients who underwent cardiac sur-
gery in our hospital from January 2002 to September
2010. The study included adult patients with AKI who re-
quired RRT after open heart surgery and survived longer
than 72 h after surgery. Patients were excluded if they
were under the age of 18, received cardiac transplantation
surgery, had end-stage renal disease (ESRD) before sur-
gery, or received preoperative RRT due to any reasons.
The DHF group included 70 patients who received DHF
between January 2002 and September 2008, and the
GDRRT group was comprised of 70 patients who were
treated with GDRRT between October 2009 and September
2010. We used pair-wise comparisons between the 2
groups regarding clinical outcomes, as well as the incidence
of adverse events. The study was approved by the
Institutional Review Board of the Shanghai Zhongshan
Hospital, which waived the requirement for informed con-
sent for the retrospective review of RRT interventions after
cardiac surgery. In our hospital, we practiced only DHF as a
therapeutic strategy for treating AKI following cardiac
surgery until 2008, and GDRRT was first introduced in
October 2008. We used paired analysis in order to reduce
the bias created by the different time periods. We collected
data for a paired analysis from 70 patients who received
DHF between January 2002 and September 2008, and from
70 patients who received GDRRT between October 2009
and September 2010. The main criteria for the paired
analysis were equal type of surgery and severity of illness,
according to acute physiology and chronic health evalua-
tions (APACHE) II [20] and sepsis-related organ failure
assessment (SOFA) scores [21].Data collection
In addition to hemodynamic and laboratory data, baseline
vital signs were also recorded in the first day of ICU
admission and then daily after nephrology consultation.
In addition, APACHE, II as well as SOFA scores and
EuroScore values [22], were computed within the first
24 h after admission to the ICU, in order to assess the se-
verity of the illness. AKI was defined as elevation of serum
creatinine (SCr) ≥ 26.4 μmol/L or 50% higher than the
baseline within 48 h, or urine output < 0.5 ml/kg/h for
more than 6 h, and staged according to the AKI Network
classification [23]. Sepsis was defined according to the
American College of Chest Physicians/Society of Critical
Care Medicine (ACCP/SCCM) Consensus Conference
Committee [24]. Recovery of kidney function was consid-
ered to be complete if the SCr was less than 44 μmol/L
above the baseline value or to be partial if the SCr
remained higher than 44 μmol/L above the baseline value
but the patient was not dialysis-dependent [9]. In-hospital
mortality rates inside and outside the ICU within 30 days
were the primary end-points of the trial. Secondary end-
points were ICU and hospital days, mechanical ventilation
days, hospitalization expenses, hemodynamic stability,




The form, frequency, and time of each session, as well as
the dose/ultrafiltration rate of DHF were fixed, assuming
that patients were in a stable state at the time of DHF ini-
tiation and that their status did not change substantially.
The indications for RRT initiation were as follows: (1)
Serum K+ ≥ 6.0 mmol/L and/or electrocardiogram abnor-
malities; (2) Arterial blood pH ≤ 7.15; (3) Urine output <
200 mL/12 h when the first dose of furosemide was up to
80 mg or the highest dose was up to 240 mg, or anuria;
(4) Rapidly rising blood urea nitrogen (BUN) or SCr; (5)
Refractory fluid overload with pulmonary edema; (6)
Severe sepsis with septic shock. HF was performed with
Baxter BM25 or Aquarius CRRT equipment using
FILTRAL 20 (AN 69, 2.05 m2 surface, GAMBRO,
Sweden). We used our hospital formula as a replacement
fluid, and the ratio of pre- and post-dilution was two-thirds,
with an ultrafiltration rate of 60-70 ml/kg/h. Vascular
access was obtained with a dual-lumen HD catheter
inserted into the internal jugular or femoral vein by the
standard Seldinger technique. Either a loading dose of
1500 IU heparin followed by an individual patient-adjusted
anticoagulation regimen or no anticoagulation was used.
GDRRT
GDRRT cannot be defined as a fixed RRT strategy, and it
is basically composed of HD, HF, and hemodiafiltration
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achieve specific goals, and various parameters were moni-
tored. The indications for RRT initiation were the same as
for DHF. The patients received a central venous catheter
capable of measuring central venous pressure (CVP), and
oxygen saturation data were fed into a computerized ECG
monitor, which also monitored heart and breathing rates,
as well as blood pressure. Fluid intake and output was re-
corded every day, and urine output was recorded every
6 h. Potential of hydrogen and arterial oxygen saturation
were monitored by blood gas analysis at least every 4 h.
Blood biochemistry and other laboratory data were tested
at least once every day. The usual HD or HF lasted about
4 h per session and were performed every day or every
other day, but for all patients, the form, frequency, and
time of each session and the dose/ultrafiltration rate were
not standardized. The procedures were all performed with
Baxter Aquarius equipment, using highly permeable mem-
branes made of polyether sulfone (1.7 m2 or 1.4 m2 surface
area, GAMBRO, Sweden) starting the first session with a
small surface area filter and increasing the filter size in fur-
ther sessions. The vascular access and replacement fluid
were the same as for DHF, and the usual HF ultrafiltration
rate was 25-35 ml/kg/h. The usual blood flow ranged from
100 to 250 ml/min and the dialysate flow was 8-10 L/h for
HD. In all GDRRT modalities, anticoagulation was per-
formed with unfractionated heparin, low-molecular-weight
heparin (LMWH), or no anticoagulation, according to the
consulting nephrologists’ decisions.
GDRRT algorithm
The goals of GDRRT are listed in Table 1, and they in-
cluded immediate and ongoing goals. The immediate
goals were correcting electrolyte disturbance and acide-
mia by providing bicarbonate or reducing hyperkalemia,
controlling volume by removing fluid overload, and im-
proving hemodynamic stability. Ongoing goals included
maintenance of fluid balance, promoting renal recovery,
weaning from vasopressors, maintenance of acid-base
and electrolyte balances, and support of organ functions.
The treatment protocol was as follows (see Figure 1). The
GDRRT strategy was decided before treatment, based on
the severity of the illness. Hemodynamically stable patients
in hypercatabolic state or with severe internal environmentTable 1 The goals of GDRRT
Solute BUN ≤ 30 mmol/L
Volume Urine output ≥ 0.5 ml/kg/h, 24 h fluid output ≥ 24 h fluid i
reduction of peripheral edema, hematocrit ≥ 30%
Electrolyte and
pH
Electrolyte and acid-base parameters normal or near norm
Hemodynamics MAP ≥ 65 mmHg without vasoactive drugs, CVP ≥ 8–12 m
BUN = blood urea nitrogen, MAP =mean arterial pressure, CVP = central venous predisturbance (defined as having a SOFA cardiovascular score
of 0 to 2) received HD or HDF, while patients without
hypercatabolic state or severe internal environment dis-
turbance or who were hemodynamically unstable (defined
as having a SOFA cardiovascular score of 3 to 4) received
HF. GDRRT was performed every day to achieve the goals
listed in Table 1, and the frequency and duration of RRT
sessions were determined depending on whether these
goals were achieved. If the goals were not achieved (e.g.,
no solute control, severe electrolyte disturbance, refractory
fluid overload, severe unstable hemodynamics), or in case
of severe sepsis, acute respiratory distress syndrome
(ARDS), or multiple organ dysfunction syndrome (MODS),
the dose was increased and the usual HD and HF session
times of about 4 h were extended to 8–10 h per session, or
even 24 h if necessary. If the goals were achieved in the
following days, the dose and frequency were reduced, and
the time of each session was shortened. When patients re-
ceiving HD turned hemodynamically unstable (i.e., when
the mean arterial pressure (MAP) was ≤ 65 mmHg, or
the average cumulative daily variability of MAP was ≥
30 mmHg) they were transitioned to HF, or continuous
treatment was administered and vasopressors or vasodila-
tors were given to maintain the MAP. The crossover from
one to the other RRT modality was decided by nephrolo-
gists. The initial form of GDRRT included 57 usual HD
and 13 HF sessions, and the main reason for conversion
from HD to HF was hemodynamic instability. During the
course of treatment, 10 patients received continued HD/
HF because of sepsis or MODS, and only one patient re-
ceived continued HDF for severe sepsis. The ultimate form
of GDRRT was usual HD 53 times and HF 17 times.Statistical analyses
Statistical analyses were performed using the SPSS soft-
ware, version 16.0. Measurement data were expressed as
means ± SD or median and quartile [M (QR)]. Paired
t-test was used for comparing baseline characteristics of
the 2 groups, and independent t-test was used for com-
paring outcomes, while chi-squared test was used to
analyze categorical data. Logistic regression analysis was
used to correct for confounding factors. P < 0.05 was
considered as statistically significant.ntake in volume overload patients, controlled acute pulmonary edema,
al: 3.5 < potassium ≤ 5.5 mmol, 7.25 ≤ pH < 7.45
mHg, SaO2 ≥ 93%
ssure, SaO2 = saturation level of oxygen in hemoglobin.
Figure 1 Scheme of the GDRRT algorithm.
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Of the 140 patients, 70 underwent GDRRT, while the
other 70 underwent DHF, and treatments in the 2 groups
included 21 valve surgeries, 13 coronary artery bypass
grafts (CABG), 19 thoracic aortic surgeries, 7 congenital
heart surgeries, and 10 combined surgeries. The body
mass index (BMI) in the GDRRT group was significantly
lower than in the DHF group (22.0 ± 3.6 vs. 23.8 ± 4.6, P =
0.025). Other baseline characteristics of the 2 groups were
not significantly different (Table 2).
Clinical outcomes
After being adjusted by logistic regression, the in-hospital
mortality in the GDRRT and DHF groups were 45.7% and
48.6%, respectively (P = 0.734). The 30-day mortality was
41.4% and 54.3% in the GDRRT and the DHF groups, re-
spectively. The median hours of ICU stay and mechanical
ventilation days in the GDRRT group were significantly
less than those in the DHF group (238.9 [119.9-483.8] vs.360.0 [178.8-552.9] hours, P = 0.026) and 6 [3-15] vs. 9 [6-
19] days, respectively, P = 0.046). There was no significant
difference in median length of hospital stay between the 2
groups (25 [14-32] vs. 23 [13-36] days, P = 0.998). The fre-
quency of RRT and the mean duration of RRT sessions
were longer in the DHF group (2 [1-6] vs. 4 [2-9], P =
0.018 and 5 ± 1 vs. 6 ± 2 hours, P < 0.01). Hospitalization
expenses were much higher in the DHF than in GDRRT
group (2307.7 ± 430.8 vs. 1515.4 ± 461.5 dollars, P < 0.01)
(Table 3).
Renal outcomes
The complete renal recovery rate was significantly higher
in the GDRRT than in DHF group (37% vs. 19%, P =
0.016). The time for complete renal recovery was shorter
in the GDRRT group (13 ± 9 vs. 22 ± 14 days, P = 0.042),
whereas there were no significant differences in partial
renal recovery rates in the 2 groups (9% vs. 15%, P =
0.409). Both maximum SCr and SCr at hospital discharge
Table 2 Baseline characteristics in the GDRRT and DHF groups
GDRRT (n =70) DHF (n = 70) P value
Male (n/%) 70 (64%) 70 (71%) 0.366
Age (y) 54 ± 15 55 ± 15 0.788
BMI (kg/m2) 22.0 ± 3.6 23.8 ± 4.6 0.025
DM (%) 16% 7% 0.118
HT (%) 33% 44% 0.165
NYHA III 44% 54% 0.119
IV 17% 28% 0.061
CPB duration (min) 116 ± 59 134 ± 52 0.065
Aortic clamping duration (min) 58 ± 38 57 ± 32 0.919
EuroSCORE
Low risk (<3) 12 (17.1%) 11 (15.7%) 0.820
Medium risk (3 − 6) 28 (40%) 25 (35.7%) 0.601
High risk (>6) 30 (42.9%) 34 (48.6%) 0.497
Pre-op BUN (mmol/L) 9.4 ± 5.0 8.9 ± 6.7 0.632
Pre-op SCr (μmol/L) 112.1 ± 74.8 119.2 ± 101.7 0.639
Renal function before RRT
BUN (mmol/L) 24.8 ± 15.2 27.3 ± 16.2 0.378
SCr (μmol/L) 334.5 ± 148.9 365.0 ± 156.3 0.250
K+ (mmol/L) 4.6 ± 1.2 4.5 ± 1.3 0.637
Oliguria (%) 48% 44% 0.683
AKIN before RRT (%)
AKIN1 19% 12% 0.160
AKIN2 31% 25% 0.840
AKIN3 50% 63% 0.211
Time from ICU admission
to RRT (d) 2 (1, 5) 2.5 (2, 5) 0.245
Sepsis (%) 18% 23% 0.381
Post-op APACHE II (24 h) 21.9 ± 5.4 22.8 ± 4.0 0.266
Post-op SOFA (24 h)
Cardiovascular 2.8 ± 1.1 2.6 ± 1.0 0.262
Respiratory 2.4 ± 1.0 2.1 ± 1.5 0.164
Renal 1.8 ± 0.9 1.7 ± 1.2 0.587
Entire SOFA Score 10.8 ± 2.5 11.4 ± 2.8 0.183
NYHA: New York Heart Association; Pre-op BUN: preoperative blood urea nitrogen; Pre-op Scr: preoperative serum creatinine; Post-op APACHE II (24 h): postoperative
acute physiology and chronic health evaluation within the first 24 h after surgery; Post-op SOFA (24 h): postoperative sepsis-related organ failure assessment within the
first 24 h after surgery.
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(561.0 ± 239.2 vs. 441.7 ± 189.9 μmol/L, P < 0.001, and
377.2 ± 265.8 vs. 275.5 ± 164.3 μmol/L, P = 0.007). There
were no significant differences in maximum BUN and
BUN at hospital discharge between the 2 groups (45.5 ±
26.1 vs. 52.2 ± 23.5 mmol/L, P = 0.226; 34.2 ± 20.9 vs.
29.6 ± 17.7 mmol/L, P = 0.356). Urinary volume after 72 h
treatment was much greater in the GDRRT than in DHF
group (1590 [450-3285] vs. 370 [84, 1365] ml, P = 0.002,
and the time to oliguria resolution was shorter in theGDRRT group (2.5 [1.0, 3.8] vs. 5 [2.5, 8.5] days, P =
0.033) (Table 4).
Hemodynamic parameters and safety of therapy
The incidence of tachycardia and blood coagulation was
significantly higher in the DHF than in the GDRRT group
(79% vs. 60%, P = 0.018; 37% vs. 21%, P = 0.041). There were
no significant differences in MAP values and in the inci-
dence of hypotension within the first 72 h of treatment be-
tween the 2 groups (82 ± 12 vs. 83 ± 15 mmHg, P = 0.664;
Table 3 Clinical outcomes of AKI patients in the GDRRT and DHF groups
GDRRT (n = 70) DHF (n = 70) P value
Hospital mortality (%) 45.7% 48.6% 0.734
30-d mortality (%) 41.4% 54.3% 0.128
Hospital stay (d) 25 (14, 32) 23 (13, 36) 0.998
ICU stay (h) 238.9 (119.9 − 483.8) 360.0 (178.8 − 552.9) 0.026
Mechanical ventilation days 6 (3 − 15) 9 ( 6 − 19) 0.046
Hospitalization expense (US$) 1515.4 ± 461.5 2307.7 ± 430.8 < 0.01
RRT frequency 2 (1 − 6) 4 (2− 9) 0.018
Duration of the RRT sessions
First (h) 4 ± 1 5 ± 1 < 0.01
Average (h) 5 ± 1 6 ± 2 < 0.01
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in the daily ultrafiltration volume between the 2 groups
(2112 ± 768 vs. 1925 ± 866 ml, P = 0.179). The major anti-
coagulant medication in the DHF group was LMH (60%),
whereas in the GDRRT group, most patients (67%) received
no anticoagulation medication (Table 5).
Discussion
Although high-dose HF can help alleviate systemic inflam-
matory responses, it also can be harmful, due to its non-
selective filtration, which can lead to the loss of heat,
nutrients, and drugs [25]. In our study, GDRRT was
mostly composed of HD, which can correct azotemia and
acid-base disorders. High-dose HF was employed only for
patients with severe sepsis, in order to support the internal
environment and extra-renal organs, and to control in-
flammation and achieve hemodynamic stability, thereby
improving immune paralysis and ventilatory functions.
However, the incidence of sepsis in our study was only
18% for the GDRRT group and 23% for the DHF patients −
lower than the previously reported values of 62.4% [9] and
46.8% in RTT patients after surgery. It has been suggestedTable 4 Renal outcomes of AKI patients in the GDRRT and DH
GDRRT (n = 70)
Max BUN (mmol/L) 52.2 ± 23.5
Max SCr (μmol/L) 441.7 ± 189.9
BUN at discharge (mmol/L) 29.6 ± 17.7
Scr at discharge (μmol/L) 275.5 ± 164.3
K+ after RRT ((mmol/L) 4.5 ± 0.8
Urinary volume after 72 h (ml) 1590 (450 − 328
Oliguria resolve time (d) 2.5 (1.0 − 3.8)
Complete renal recovery (%) 37%
Time for complete renal recovery (d) 13 ± 9
Partial renal recovery (%) 9%
RRT independence at discharge (%) 42%
Max BUN =maximum blood urea nitrogen, Max SCr =maximum serum creatinine.that HD often results in hemodynamic instability, but in
this study, hypotension occurred at similar rates during
intermittent HD sessions in the 2 groups, and tachycardia
occurred more frequently in the DHF group. This can be
explained by the low ultrafiltrate rate, which maintained
stable hemodynamics in the GDRRT group, because the
HD dose in the DHF group was significantly higher than in
the GDRRT group (63.7 vs. 24.2 ml/kg/h). These values
were also similar to the previously published values of
57 ml/kg/h for IRRT and 42 ml/kg/h for continued
veno-veno HF (CVVH) treatment for cardiac surgery
AKI patients [26]. The lower ultrafiltrate rate also reduced
the need for anticoagulant medication and led to a lower
incidence of blood coagulation in the GDRRTgroup.
The absence of complete renal recovery from AKI is
one of the major risk factors of ESRD [27]. Bagshaw
et al. reported that, of 240 critically ill patients who re-
quired dialysis, 32% were on chronic renal replacement
therapy at hospital discharge and 22% persisted on dialy-
sis after 1 year. Others also suggested that one of the
purposes of RRT in treating AKI should be the promo-
tion of renal function recovery and independence fromF groups
DHF (n = 70) P value
45.5 ± 26.1 0.226
561.0 ± 239.2 < 0.001
34.2 ± 20.9 0.356
377.2 ± 265.8 0.007
4.8 ± 0.5 0.008
5) 370 (84− 1365) 0.002
5 (2.5 − 8.5) 0.033
19% 0.016
22 ± 14 0.042
15% 0.409
29% 0.111
Table 5 Hemodynamic parameters and adverse events within the first 72 h of treatment
GDRRT (n = 70) DHF (n = 70) P value
Tachycardia (%) 60% 79% 0.018
MAP (mmHg) 82 ± 12 83 ± 15 0.664
Hypotension (%) 38% 40% 0.862
Blood coagulation (%) 21% 37% 0.041
Daily ultrafiltration volume (ml) 2112 ± 768 1925 ± 866 0.179
Anticoagulant therapies
Unfractionated heparin 5% 20% < 0.01
LMWH 28% 60% < 0.01
No therapy 67% 20% < 0.01
Dialysate + filtration rate (ml/kg/h) 24.2 ± 11.1 63.7 ± 12.6
MAP =mean arterial pressure; LMWH = low-molecular-weight heparin.
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dialysis dose doesn’t appear to have a strong influence
on renal recovery [9]. In our study, GDRRT led to sig-
nificantly greater elimination of BUN and SCr, along
with correction of hyperkalemia (Table 4). GDRRT was
mainly composed of bedside HD, which may correct
azotemia and electrolyte disorders more effectively than
DHF. Because of the flexibility of GDRRT regarding dose
and treatment time, urinary volume after 72 h of treat-
ment was much higher and oliguria resolved much faster
in the GDRRT group, which may have resulted in better
renal outcome.
Even though treatment with GDRRT did not result in
a survival advantage over DHF, the complete renal re-
covery rate was significantly higher in the GDRRT group
compared with the DHF group (37% vs. 19%, P = 0.016)
and less time was necessary for renal recovery (13.9 vs.
22.14 days, P = 0.042). The lack of a statistically signifi-
cant difference in hospital mortality between the 2
groups might have been due to the small sample size.
Furthermore, DHF is beneficial for sepsis, the incidence
of which was higher in the DHF group, and this might
have improved the overall outcome.
Our study has several limitations. It was a single-center
study with a small sample size, and the time of the survey
period may have had some influence on the result, due to
changes in surgery procedures and other clinical treat-
ments, but our in-hospital mortality rate was comparable
to the previously published rates of 38.8% − 59% for car-
diac surgery RTT patients [8,9,11,26].Conclusions
Our results suggest that GDRRT is safe and effective for
patients with AKI after cardiac surgery and is superior
to DHF for improving renal recovery. In addition, it re-
duces hospitalization time and expenses. GDRRT can be
applied to most AKI patients after cardiac surgery, whileDHF may be more suitable for critically ill AKI patients
with sepsis or MODS.
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